The strong financial performance and robust cash position support the company’s 2026 outlook and buyback. Traders should monitor upcoming Phase 3 data for REZZAYO in Q2 2026 as a key catalyst.
CRMD drugs
CRMD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $6.30entry
- T+1 · 9mo ago +2.54%α +3.85% · $6.46
- T+5 · 8mo ago +1.59%α +3.82% · $6.40
- T+20 · 8mo ago +11.90%α +15.69% · $7.05
- T+60 · 6mo ago +34.13%α +22.83% · $8.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net income, a turnaround from a $17.9M loss in 2024. Growth was fueled by DefenCath sales and the full-quarter contribution from the Melinta acquisition. The company reiterated 2026 guidance and announced a $75M share repurchase program.
Key Financial Metrics
Key Facts
- Q4 2025 net revenue was $128.6 million, up 312% from $31.2 million in Q4 2024
- Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million including Melinta
- Q4 2025 net income was $14.0 million ($0.16 diluted EPS), compared to $13.5 million ($0.20 diluted EPS) in Q4 2024
- Full-year 2025 net income was $163.1 million ($2.04 diluted EPS), versus a $17.9 million loss in 2024
- Adjusted EBITDA was $77.2 million in Q4 2025, up from $15.3 million in Q4 2024
- Company reiterated 2026 guidance: $300–$320M revenue and $100–$125M adjusted EBITDA
- Announced $75 million share repurchase program
- Cash and short-term investments totaled $148.5 million at year-end
Financial Impact
Revenue grew over 600% YoY, driven by acquisition and commercial execution. Net income swung from a $17.9M loss to $163.1M profit. Adjusted EBITDA nearly quintupled in Q4.
Risk Factors
- Revenue growth heavily influenced by the Melinta acquisition; organic growth less clear
- Q4 net income included a $42.4M tax expense tied to deferred tax assets, which may not repeat
- 2026 guidance is flat to down on revenue despite strong 2025 results, suggesting near-term moderation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250043 |
Track record
21 reports on CRMD
8 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +34.13% at T+60 after the Mar 5, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $4.84 Now $4.82 +0.41% settles Nov 19
- Nov 10, 20266d ago DEFA14A Neutral 6/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $5.30 Now $4.82 −9.06% settles Nov 18
- Nov 9, 20267d ago DEFA14A Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 9, 20267d ago 8-K Neutral 6/10 Entry $5.47 to $4.82 Now $4.82 −11.88% ▼ −11.88% −10.19% vs SPY
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 4/10 Entry $5.39 to $5.47 Now $4.82 −10.58% ▲ +1.48% +1.41% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $7.38 to $7.94 Now $4.82 −34.69% ▲ +7.59% +7.73% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $7.38 to $8.03 Now $4.82 −34.69% ▲ +8.74% +8.88% vs SPY
- Aug 13, 202613w ago 8-K Neutral 5/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers